Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024
Continued to advance pipeline of small molecule. | May 15, 2023
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 SeriesAnn.
Key HighlightsNominated EB-373 as lead development candidate for the treatment of anxiety disordersEB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s EVM201 Series and developed leveraging the Company’s Psybrary™ drug discovery platformEstablished Australia-based subsidiary, Enveric The.
Key Highlights
Nominated EB-373 as lead development candidate for the treatment of anxiety disorders
EB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s. | April 3, 2023
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.